Clinical Trial Update: Nivolumab in Recurrent and/or Metastatic SCCHN [Phase 2]

View source ↗

Summary

Phase 2 trial update for nivolumab in recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) that is platinum-refractory, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: UNICANCER | Conditions: Recurrent and/or Metastatic Platinum-refractory SCCHN | Phase 2 | Status: COMPLETED